Management of Cirrhosis in Diabetes: A Pragmatic Approach to the Patient

Clicks: 6
ID: 324696
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #48 of 362 articles by views in the journal of clinical endocrinology & metabolism

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 362 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
As the global burden of cirrhosis shifts toward metabolic dysfunction-associated steatotic liver disease (MASLD), diabetes and metabolic syndrome act as key upstream drivers of liver injury. At the same time, diabetes is increasingly recognized even in cirrhosis of non-metabolic etiologies, including viral hepatitis, reflecting both shared risk factors and cirrhosis-related disturbances in glucose homeostasis. This coexistence amplifies morbidity, mortality, and therapeutic complexity, while conventional diabetes paradigms often prove inadequate in management of cirrhosis. This review synthesizes current evidence and proposes a pragmatic framework for managing diabetes across the full spectrum of cirrhosis. We examine the evolving concept of hepatogenous diabetes, limitations of HbA1c in advanced liver disease, and the complementary roles of oral glucose tolerance testing and continuous glucose monitoring in improving diagnostic accuracy. The pharmacologic landscape is critically evaluated, integrating contemporary diabetes guidelines with hepatic stage-specific considerations. Metformin remains the backbone of therapy in compensated cirrhosis. Among newer agents, GLP-1 receptor agonists and SGLT2 inhibitors show promise in compensated disease, particularly in patients with MASLD and cardio-renal comorbidities. In contrast, sulfonylureas, insulin secretagogues, and agents associated with fluid retention require caution or avoidance as hepatic reserve declines. Insulin therapy remains the cornerstone in decompensated cirrhosis and during hospitalization, where conservative dosing and dynamic titration are essential to minimize hypoglycemia. The review emphasizes nutritional optimization, frequent reassessment, and coordinated hepatology-endocrinology care. As diabetes in cirrhosis increasingly reflects the convergence of two metabolic disorders, management must prioritize hepatic safety, metabolic stability, and individualized outcomes over rigid glycemic targets.
Reference Key
openalex_W7202177204 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ashish Kumar, Rita Basu
Journal the journal of clinical endocrinology & metabolism
Year 2026
DOI
10.1210/clinem/dgag321
URL
https://doi.org/10.1210/clinem/dgag321
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.